Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab in pediatric C. difficile infection
NCT03182907Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of bezlotoxumab in Clostridioides difficile infection (CDI), sponsored by Merck & Co.. Started Mar 2018; status: completed.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03182907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182907.